These two studies from Mukherjea and colleagues [476,541] not only confirm Nox3 expression in the rat cochlea, the rather harmful ROS production during ototoxic drug applications and cisplatin-mediated increase of Nox3 expression, but also nicely demonstrate that targeting of Nox3 via siRNA shows promising potentials for a therapeutic treatment of hearing loss. The gene discussed is NOX3; the disease is hearing loss disorder.